Steady-State Plasma Imatinib Levels in 142 GIST Patients Distribution, Dose, Dose Escalation, and Response Laura K Nolden 1 , Linyee Shum 2 , Amaury Dumont 1 , Shreyaskumar Patel 1 , Dejka M Araujo 1 , Joseph A Ludwig 1 , Vinod Ravi 1 , Suzanne George 3 , Saroj Vadhan-Raj 1 , Robert S Benjamin 1 , Jonathan C Trent 1 1 UT-MD Anderson Cancer Center, Department of Sarcoma Medical Oncology and the Sarcoma Research Center; Houston, Texas, United States; 2 Avantix Laboratories, Inc., New Castle, Delaware, United States; 3 Dana-Farber Cancer Institute, Center for Sarcoma and Bone Oncology, Boston, Massachusetts, United States
23
Embed
Steady-State Plasma Imatinib Levels in 142 GIST Patients Distribution, Dose, Dose Escalation, and Response Laura K Nolden 1, Linyee Shum 2, Amaury Dumont.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Steady-State Plasma Imatinib Levels in 142 GIST Patients
Distribution, Dose, Dose Escalation, and Response
Steady-State Plasma Imatinib Levels in 142 GIST Patients
Distribution, Dose, Dose Escalation, and Response
Laura K Nolden1, Linyee Shum2, Amaury Dumont1, Shreyaskumar Patel1, Dejka M Araujo1, Joseph A Ludwig1, Vinod Ravi1, Suzanne George3, Saroj Vadhan-Raj1, Robert S Benjamin1, Jonathan C Trent1
1UT-MD Anderson Cancer Center, Department of Sarcoma Medical Oncology and the Sarcoma Research Center; Houston, Texas, United States; 2Avantix Laboratories, Inc., New Castle, Delaware, United States; 3Dana-Farber Cancer Institute, Center for Sarcoma and Bone Oncology, Boston, Massachusetts, United States
Laura K Nolden1, Linyee Shum2, Amaury Dumont1, Shreyaskumar Patel1, Dejka M Araujo1, Joseph A Ludwig1, Vinod Ravi1, Suzanne George3, Saroj Vadhan-Raj1, Robert S Benjamin1, Jonathan C Trent1
1UT-MD Anderson Cancer Center, Department of Sarcoma Medical Oncology and the Sarcoma Research Center; Houston, Texas, United States; 2Avantix Laboratories, Inc., New Castle, Delaware, United States; 3Dana-Farber Cancer Institute, Center for Sarcoma and Bone Oncology, Boston, Massachusetts, United States
BackgroundBackground
Several studies from patients with GIST and CML suggest a correlation between imatinib steady-state plasma trough levels and patient outcomes
Several studies from patients with GIST and CML suggest a correlation between imatinib steady-state plasma trough levels and patient outcomes
Demetri, G et al. J Clin Oncol; 2009Demetri, G et al. J Clin Oncol; 2009
Larson, RA et al. Blood; 2008Larson, RA et al. Blood; 2008
Picard, S et al. Blood; 2007Picard, S et al. Blood; 2007
RationaleRationale
Variability in imatinib plasma levels could occur for several reasons:• Gastrectomy
• Unadjusted dosing (weight, BSA)
• Race, gender, age
• Duration of therapy
• Concomitant medications
Variability in imatinib plasma levels could occur for several reasons:• Gastrectomy
• Unadjusted dosing (weight, BSA)
• Race, gender, age
• Duration of therapy
• Concomitant medications
Blanke CD et al. J Clin Oncol, 2008Blanke CD et al. J Clin Oncol, 2008
Judson I et al. Cancer Chemother Pharmacol. 2005Judson I et al. Cancer Chemother Pharmacol. 2005
ObjectivesObjectives
• To determine the distribution of plasma imatinib levels in patients with GIST
• To determine factors that correlate with plasma imatinib level
• To determine the incremental effects of imatinib dose escalation
• To explore the median plasma levels and outcomes of patients with KIT exon 9 mutation
• To determine the distribution of plasma imatinib levels in patients with GIST
• To determine factors that correlate with plasma imatinib level
• To determine the incremental effects of imatinib dose escalation
• To explore the median plasma levels and outcomes of patients with KIT exon 9 mutation
Patient Response AssessmentPatient Response Assessment• Response was assessed within the first 4 months of
imatinib exposure
• Response was classified according to Choi criteria:
– CR, no radiographic evidence of GIST
– PR, > 10% decrease in GIST size or > 15% decrease in GIST radiodensity
– SD, less than 10% decrease or increase in GIST size and does not meet criteria of PR by radiodensity
– PD, > 10% increase in GIST size
– ND, patient underwent resection and no response could be assessed
• Response was assessed within the first 4 months of imatinib exposure
• Response was classified according to Choi criteria:
– CR, no radiographic evidence of GIST
– PR, > 10% decrease in GIST size or > 15% decrease in GIST radiodensity
– SD, less than 10% decrease or increase in GIST size and does not meet criteria of PR by radiodensity
– PD, > 10% increase in GIST size
– ND, patient underwent resection and no response could be assessed
Heinrich et al, J Clin Oncol 2007Heinrich et al, J Clin Oncol 2007
Progression-Free SurvivalKIT Genotype
Progression-Free SurvivalKIT Genotype
p = 0.08
p = 0.32
Imatinib Plasma LevelsKit Genotype
Imatinib Plasma LevelsKit Genotype
Genotype
Median Imatinib
Dose(mg)
Range (mg)
Average Imatinib
Plasma Level (ng/mL)
Range (ng/mL)
Exon 9800
400 - 1200 1741 446 - 4285
Exon 11 400 200 - 800 1470 256 - 4582
Wild-type 400 400 - 800 1497 673 - 2793
Other 400 400 - 800 1441 386 - 2904
SummarySummary• Imatinib plasma levels in our patients ranged from
256 – 4582 with a first quartile cutoff of 851ng/mL, lower than the published literature.
• Imatinib plasma levels correlated with age, gender, imatinib dose and Choi response
• Dose escalation of imatinib by 100 mg resulted in an average 296 ng/mL plasma level increase.
• Patients with KIT exon 9 mutation were treated with higher dose of imatinib, had higher plasma levels, and had a PFS similar to that of patients with exon 11 mutation
• Imatinib plasma levels in our patients ranged from 256 – 4582 with a first quartile cutoff of 851ng/mL, lower than the published literature.
• Imatinib plasma levels correlated with age, gender, imatinib dose and Choi response
• Dose escalation of imatinib by 100 mg resulted in an average 296 ng/mL plasma level increase.
• Patients with KIT exon 9 mutation were treated with higher dose of imatinib, had higher plasma levels, and had a PFS similar to that of patients with exon 11 mutation
Randomized Study of Imatinib Plasma SARC-019
Randomized Study of Imatinib Plasma SARC-019
Advanced GIST on Imatinib 400mg/day (N=400)
Measure Imatinib Plasma Level
<1100 ng/mL (N=100) >1100 ng/mL (N=300)
Randomize
Arm AImatinib 400mg/day
Plasma Level TestingNo Dose Adjustment
Arm BImatinib 600mg/day
Plasma Level TestingAdjust Dose
Arm CImatinib 400mg/day
Plasma Level TestingNo Dose Adjustment
Arm D (Exon 9)Imatinib 4-800mg/dayPlasma Level TestingNo Dose Adjustment
Control Cohort (N=50)
KIT Genotype
PIs Suzanne George and Jon Trent
AcknowledgementsAcknowledgements
Robert Benjamin
Shreyaskumar Patel
Dejka Araujo
Joseph Ludwig
Vinod Ravi
Alex Lazar
Robert Benjamin
Shreyaskumar Patel
Dejka Araujo
Joseph Ludwig
Vinod Ravi
Alex Lazar
Supported by a grant from the Institute for Personalized Cancer Therapy at M. D. Anderson Cancer Center
Suzanne George
Linyee Shum
Saroj Vadhan-Raj
Wei Qiao
Jon Trent
Billy Wang
Suzanne George
Linyee Shum
Saroj Vadhan-Raj
Wei Qiao
Jon Trent
Billy Wang
Concomitant MedicationsConcomitant Medications• Cyp3A4 inhibitors may increase TKIs
– ketoconazole, itraconazole, erythromycin, and clarithromycin, grapefruit, star fruit
• CYP3A4 inducer may decrease TKIs– dexamethasone, phenytoin, carbamazepine,
rifampin (80%), phenobarbital or St. John's Wort
• CYP3A4, CYP2C8, CYP2C9, CYP2D6 are competitively inhibited by TKIs– Warfarin, midazolam, macrolides, caffeine
• Cyp3A4 inhibitors may increase TKIs– ketoconazole, itraconazole, erythromycin, and
clarithromycin, grapefruit, star fruit
• CYP3A4 inducer may decrease TKIs– dexamethasone, phenytoin, carbamazepine,
rifampin (80%), phenobarbital or St. John's Wort
• CYP3A4, CYP2C8, CYP2C9, CYP2D6 are competitively inhibited by TKIs– Warfarin, midazolam, macrolides, caffeine